Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

From Fighting Inflammation To Regenerating Cells: How Jupiter Neurosciences Is Putting The Pep Back In Our Step As We Age

By Meg Flippin Benzinga

Jupiter Neurosciences is a clinical-stage pharmaceutical company developing drugs to treat neuroinflammation, with a current focus on central nervous system (CNS) disorders such as Alzheimer's and Parkinson's, and rare diseases. The company also has a direct-to-consumer longevity product line called  Nugevia™, which is aimed at generating near-term revenue while maintaining momentum in its clinical pipeline. 

At the heart of Jupiter Neurosciences' business is JOTROL™, which is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The company said a phase 1 trial showed it to achieve blood plasma levels 8-10-fold higher than naïve resveratrol.

“I like cash flow and biotech is not cash flow,” Rosen told Benzinga about the company’s direct-to-consumer line. “You hope you get good results, you raise some money and you hope for good results.” Nugevia's first three formulations target mitochondrial support, mental clarity and "beauty from within" and will be sold via a direct-to-consumer (DTC) model starting in the third quarter.  “The longevity and aging market is exploding,” says Rosen. 

Jupiter Neurosciences is going after CNS diseases and the longevity markets because of multi-functional benefits. On the one hand, it can reduce and potentially eliminate inflammation, which is key to treating brain diseases such as Alzheimer’s and Parkinson's, says Rosen. It can also increase mitochondria, which regenerate cells. 

Watch the full interview here: 
https://www.youtube.com/watch?v=RdPdpeSngww

Featured image from Shutterstock.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.